Skip to content
Loading…
Aspen Neuroscience Inc., a clinical-stage developer of cell therapies, fell 2% after raising about $140.6 million in a US initial public offering.
To respect copyright, we link to the source rather than republishing the full text. Read the complete article on Bloomberg.